- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback. (Pubmed Central) - Nov 16, 2024
Subsequently, after mRNA COVID-19 vaccination, memory B cell differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating memory B cell responses to infection, and single mAb administration can continue to impact memory B cell responses to additional antigen exposures months later.
- |||||||||| Journal: Identification of Antibody-Resistant SARS-CoV-2 Mutants via N4-Hydroxycytidine Mutagenesis. (Pubmed Central) - Nov 13, 2024
From the Omicron B.1.1.529 variant, the strongly selected mutations were: Bebtelovimab - V445A; Sotrovimab - E340K and K356M; Cilgavimab - K444R, V445A and N450D...Notably, many of the identified resistance-conferring mutations are prevalent in real-world SARS-CoV-2 variants, but some of them (G485S, D428G, and K462E) have not yet been observed in circulating strains. Our approach offers a strategy for predicting the therapeutic efficacy of antibodies against emerging virus variants.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection. (Pubmed Central) - Oct 25, 2024
In conclusion, the onset of an IgM-dominated endogenous immune response in an immunocompromised patient coincided with the appearance of additional mutations in the NTD and RBD of S in a bamlanivimab-resistant virus. Although virus elimination was ultimately achieved, this humoral immune response escaped detection by routine diagnosis and created a situation temporarily favouring the rapid emergence of various antibody escape mutants with known epidemiological relevance.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
COVID-ASSOCIATED ORGANIZING PNEUMONIA WITH CLAD IN A LUNG TRANSPLANT PATIENT (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6542;
Patients with post COVID pneumonia must be evaluated for organizing pneumonia in order to initiate early treatment. In addition, lung transplant patients who develop COVID infection must be monitored for decline in their lung function.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response. (Pubmed Central) - Sep 9, 2024
P2/3
In this study, we assessed host neutralizing antibody (nAb) responses against both ancestral virus and those with treatment-emergent E484K bamlanivimab resistance mutations...Emerging drug resistance after SARS-CoV-2-specific mAb therapy led to a heightened host neutralizing antibody response to the mAb-resistant variant that was associated with eventual viral clearance. This demonstrates the interplay between the antiviral treatment-directed viral evolution and subsequent host immune response in viral clearance.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Clinical, Journal: Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment. (Pubmed Central) - Aug 21, 2024
Assessment of immune responses in the four individuals treated with the 700 mg of bamlanivimab with emerging mAb resistance demonstrated a stronger anti-N IgG response (MSD) at day 28 (median 2.18 log BAU/mL) compared to participants treated with bamlanivimab who did not develop resistance (median 1.55 log BAU/mL). These data demonstrate the utility in using multiplex immunoassays for characterizing the immune responses with and without treatment in a study population and provide evidence that monoclonal antibody treatment in acute COVID-19 may have a modest negative impact on development of host IgG responses.
- |||||||||| ivermectin oral / Generic mfg.
Journal: Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports. (Pubmed Central) - Aug 4, 2024
Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).
- |||||||||| Biomarker, Clinical data, Journal: Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. (Pubmed Central) - Jun 8, 2024
The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl). Patients admitted to hospital with less favourable 5-day biomarker trajectories had worse prognosis, suggesting that persistent viral burden might drive inflammation in the pathogenesis of COVID-19, identifying patients that might benefit from escalation of antiviral or anti-inflammatory treatment.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly
Journal: Biophysical principles predict fitness of SARS-CoV-2 variants. (Pubmed Central) - May 31, 2024
Our study sheds light on the impact of specific mutations on viral fitness and delivers a tool for predicting the future epidemiological trajectory of previously unseen or emerging low-frequency variants. These insights offer not only greater understanding of viral evolution but also potentially aid in guiding public health decisions in the battle against COVID-19 and future pandemics.
- |||||||||| REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
Clinical data, Retrospective data, Review, Journal: Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. (Pubmed Central) - May 9, 2024
These insights offer not only greater understanding of viral evolution but also potentially aid in guiding public health decisions in the battle against COVID-19 and future pandemics. No abstract available
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Retrospective data, Review, Journal: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis. (Pubmed Central) - Apr 15, 2024
No abstract available Although the results suggest the efficacy and safety of bamlanivimab in COVID-19 patients, further research is required to confirm the efficacy of this drug for the current circulating SARS-CoV-2 variants.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Organizing Pneumonia With Surgical Pathology Positive for SARS-CoV2 a Year After Initial COVID-19 Diagnosis Despite Negative COVID-19 PCR From Nasal Swabs and Bronchial Alveolar Lavage in a Lymphopenic Cancer Patient (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4077;
He received monoclonal antibody, Bamlanivimab, with little improvement...Given symptoms, negative infectious work up including fungal markers and PET scan with new bilateral ground glass opacities (GGOs), he was started on prednisone 10mg daily for presumed long COVID-19...He tested COVID PCR negative multiple times and was treated for presumed pneumonia with Augmentin and Levofloxacin with minimal improvement in symptoms...While COVID PCR from a BAL has high sensitivity, the patient tested negative multiple times with the diagnosis ultimately made with immunohistochemical stains from biopsy. Steroids continue to be the treatment of choice for PCOP.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: Long COVID After Bamlanivimab Treatment. (Pubmed Central) - Aug 31, 2023
P2/3
Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Trial completion: TICO: ACTIV-3: Therapeutics for Inpatients With COVID-19 (clinicaltrials.gov) - Aug 25, 2023
P3, N=2753, Completed,
The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention. Active, not recruiting --> Completed
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Darzalex (daratumumab) / J&J
Journal: Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19. (Pubmed Central) - Jul 29, 2023
The neutralizing antibody decreases overall mortality. Evidence from the current study and previous publications suggest that testing of neutralizing antibody post-SARS-CoV-2 vaccination in MM patients may be needed in reducing COVID-19 risk.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Trial completion: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Jul 27, 2023
P2/3, N=4044, Completed,
Evidence from the current study and previous publications suggest that testing of neutralizing antibody post-SARS-CoV-2 vaccination in MM patients may be needed in reducing COVID-19 risk. Active, not recruiting --> Completed
- |||||||||| Enrollment change, Trial termination: UPMC OPTIMISE-C19 Trial, a COVID-19 Study (clinicaltrials.gov) - Jun 15, 2023
P4, N=4571, Terminated,
Because of significant drug-drug interactions between nirmatrelvir-ritonavir and immunosuppressive agents as well as N=23858 --> 4571 | Completed --> Terminated; Emergency Use Authorizations for monoclonal antibodies withdrawn
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
Trial completion, Trial completion date, Trial primary completion date: BLAZE-1: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - May 12, 2023
P2/3, N=3307, Completed,
BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants. Recruiting --> Completed | Trial completion date: Oct 2023 --> Feb 2023 | Trial primary completion date: Oct 2023 --> Feb 2023
- |||||||||| REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (Pubmed Central) - May 1, 2023
mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Enrollment change, Trial termination: CATCO-NOS: Treatment of Nosocomial COVID-19 (clinicaltrials.gov) - Apr 19, 2023
P4, N=46, Terminated,
Our HCT cohort patients had less hospitalization rate compared with HM cohort patients. N=648 --> 46 | Suspended --> Terminated; Equipoise requirement no longer met.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly, bebtelovimab (LY-CoV1404) / AbCellera, Eli Lilly
Journal: Insights on the interaction of SARS-CoV-2 variant B.1.617.2 with antibody CR3022 and analysis of antibody resistance. (Pubmed Central) - Mar 21, 2023
Several interactions with CR3022 have appeared compared to Wild for Delta variant, and hence, it is suggested that modification on the CR3022 antibody could further improve for the prevention of viral spread. Antibody resistance decreased significantly due to numerous hydrogen bond interactions which clearly indicate that these marketed/launched vaccines (etesevimab) will be effective for Delta variants.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly
Journal: Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study. (Pubmed Central) - Mar 2, 2023
Early treatment of the SARS-CoV-2 virus effectively achieves a better recovery from disease and reduces lung involvement after three months as evaluated with LUS. Despite extrapolation to the general population may be done with caution, based on our data this ultrasound method is also effective for evaluating and following lung involvement in COVID-19 patients.
- |||||||||| REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly
Observational data, Retrospective data, Journal: Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital. (Pubmed Central) - Feb 24, 2023
Larger studies of the use of mAb therapy to treat COVID-19 in this population are needed. Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths.
- |||||||||| REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series. (Pubmed Central) - Jan 14, 2023
If variant identification becomes a more accessible tool in outpatient centers or EDs, more targeted therapeutic options may be considered. MAb treatment was well tolerated by children in this cohort.
- |||||||||| Review, Journal: A review of COVID-19 therapeutics in pregnancy and lactation. (Pubmed Central) - Dec 16, 2022
Moving forward, diligent follow-up and documentation of outcomes in pregnant people treated with these agents will be essential to advance our understanding. Greater regulatory push and incentives are needed to ensure studies to obtain pregnancy data are expedited.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: Structural evolution of Delta lineage of SARS-CoV-2. (Pubmed Central) - Nov 27, 2022
We observed that the detected mutations in the Spike of the B1.617.2 variant of concern can cause extensive structural changes compatible with the described variation in immunogenicity, secondary and tertiary structure, oligomerization potency, Furin cleavability, and drug targetability. Compared to the Spike of Wuhan lineage, the B.1.617.2 Spike is more stable and binds to the Angiotensin-converting enzyme 2 (ACE2) with higher affinity.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Journal: Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. (Pubmed Central) - Nov 17, 2022
Overall, our findings suggest that the quantity and quality of SARS-CoV-2-specific T cell memory was robust in individuals who received bamlanivimab for acute COVID-19. Receipt of bamlanivimab during acute COVID-19 neither diminished nor enhanced SARS-CoV-2-specific cellular immunity.
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Clinical, P2 data, Journal: Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. (Pubmed Central) - Nov 4, 2022
P2/3
These results highlight the potential for rapid emergence of resistance during mAb monotherapy treatment that results in prolonged high-level respiratory tract viral loads. Assessment of viral resistance should be prioritized during the development and clinical implementation of antiviral treatments for COVID-19.
|
